EP1516013A1 - Compositions de mousse hydrophile presentant des proprietes antibacteriennes - Google Patents

Compositions de mousse hydrophile presentant des proprietes antibacteriennes

Info

Publication number
EP1516013A1
EP1516013A1 EP03753094A EP03753094A EP1516013A1 EP 1516013 A1 EP1516013 A1 EP 1516013A1 EP 03753094 A EP03753094 A EP 03753094A EP 03753094 A EP03753094 A EP 03753094A EP 1516013 A1 EP1516013 A1 EP 1516013A1
Authority
EP
European Patent Office
Prior art keywords
hydrophilic
foam composition
silver metal
foam
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03753094A
Other languages
German (de)
English (en)
Inventor
Robert W. Sessions
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferris Pharmaceuticals Inc
Original Assignee
Ferris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferris Pharmaceuticals Inc filed Critical Ferris Pharmaceuticals Inc
Publication of EP1516013A1 publication Critical patent/EP1516013A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/0066—Use of inorganic compounding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4833—Polyethers containing oxyethylene units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2207/00—Foams characterised by their intended use
    • C08J2207/12—Sanitary use, e.g. diapers, napkins or bandages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
    • C08J2375/04—Polyurethanes

Definitions

  • the present invention relates to novel foam products and, more particularly, to liighly absorbent hydrophilic polyurethane foam compositions which have antimicrobial as well as liquid release and exchange characteristics.
  • Absorbent pads such as for use in contact with the skin for absorbing body fluids, are well known. Such pads are useful for numerous applications, including for example as a diaper, sanitary napkin, bandage, wound dressing or the like.
  • Absorbent pads have been made of a wide variety of materials. For example, such pads have been made using graft copolymers, as described in U.S. Pat. No. 4,055,184.
  • the absorbent pad therein described includes an absorbent mass comprising a solid finely- divided mixture of a completely hydrolyzed starch-polyacrylonitrile graft copolymer and a non-irritating and non-toxic water-soluble basic material such as, for example, sodium bicarbonate, which may be admixed with and distributed in a highly porous web or batt of cotton linters, layers of creped tissue or a mass of shredded polyurethane foam particles.
  • Pads in the form of a foam and which have been made from various superabsorbent materials are likewise known. For example, U.S. Pat. No.
  • 4,394,930 discloses an absorbent foam product prepared by mixing together a solid, particulate, water- insoluble, water-swellable polymer such as "hydrogels", “hydrocolloids” or “superabsorbents” which are lightly cross-linked polymers containing a plurality of hydrophilic groups, such as carboxyl, carboxamide, sulfonate salt or hydroxyl groups, a blowing agent, and a liquid polyhydroxy organic compound and allowing the mixture to foam.
  • a solid, particulate, water- insoluble, water-swellable polymer such as "hydrogels", “hydrocolloids” or “superabsorbents” which are lightly cross-linked polymers containing a plurality of hydrophilic groups, such as carboxyl, carboxamide, sulfonate salt or hydroxyl groups, a blowing agent, and a liquid polyhydroxy organic compound and allowing the mixture to foam.
  • U.S. Pat. No. 4,497,914 discloses an ostomy gasket composition derived from the non-aqueous reaction of a polyisocyanate and a polyoxyalkylene polyol.
  • a hydrophilic filler such as hydroxyethylcellulose, hydroxypropylcellulose or mixtures thereof, are incorporated into the polyol phase prior to reaction.
  • Hydrophilic cross-linked polyurethane foams are disclosed in U.S. Pat. No. 3,903,232. Such foams are prepared by reacting particular isocyanate-capped polyoxyethylene polyols having an isocyanate functionality greater than two with large amounts of an aqueous reactant, preferably water. The foam is said to be useful for the absorption of body fluids and may be used for external body cleaning, for internal body usage, such as is necessary in dental and medical applications, and as intimate absorptive products such as diapers, sanitary napkins, catamenial devices and the like. [0009] Other adsorbent pads using hydrophilic foam include U.S. Pat. No.
  • 3,961,629 which discloses a hydrophilic polyurethane foam in which the foam pores have a surfactant coating to accelerate absorption of body fluids into the pores at medically acceptable rates.
  • the foam is rendered hydrophilic by coating the pore walls with a thin layer of a surfactant.
  • Hygroscopic agents such as glycerin as well as other agents, such as germicidal and therapeutic agents, may be incorporated into the foam.
  • U.S. Pat. No. 4,664,662 discloses an absorbent wound dressing which comprises an absorbent foam material retained in a water permeable, porous bag.
  • the absorbent foam is preferably a hydrophilic polyurethane foam which can be made from HYPOL isocyanate- capped polyether prepolymer marketed by W. R. Grace and Co. and non-ionic surfactants.
  • Physiologically active components such as local anaesthetics, antibacterial agents, antifungal agents and the like which are compatible with the absorbent material may be incorporated into the wound dressing.
  • Hydrophilic polyurethane foam compositions are also disclosed in U.S. Pat. No. 4,339,550.
  • the hydrophilic foam composition is prepared by the "in situ" reaction of an isocyanate-capped polyether prepolymer having a functionality of from about 2 to about 8, water, and a chemically compatible, essentially non-polar, volatile organic compound.
  • the foam is stated to be capable of achieving a sustained, controlled release of the volatile materials from the foam structure.
  • Suitable "control release" ingredients for use in controlling the rate of release of the volatile ingredients include polyols, such as propylene glycol and glycerin, and materials classified as gums.
  • Hydrophilic polyurethane foam compositions and methods for their preparation are also disclosed in U.S. Patents 5,916,928, 5,254,301, 5,065,752, and 5,064,653, each of which is incorporated by reference.
  • the present invention meets the foregoing and other needs by providing an open-celled, flexible polyurethane foam composition that is hydrophilic, highly absorbent and which inhibits microbial growth.
  • the composition may desirably include an adjuvant that is capable of being released from the foam in the presence of an external liquid, the liquid being preferentially absorbed by the foam composition.
  • a more detailed object of the present invention is to provide a foam composition which is capable of releasing an adjuvant to a designated situs and which is capable of absorbing external liquids from that situs.
  • a related object is to provide such a polyurethane foam composition which will tightly hold the external fluid once it is absorbed.
  • the present invention is predicated on the discovery of a highly absorbent hydrophilic open-celled polyurethane foam composition that inhibits microbial growth, desirably within the foam composition as well as at the wound situs. This inhibition is obtained by the incorporation of a silver-containing metal (or alloys thereof) as particulates that are substantially uniformly dispersed throughout the foam composition.
  • the composition may desirably include an adjuvant and is capable of releasing at least a portion of the adjuvant while preferentially absorbing external liquid upon exposure of the foam composition to the external liquid, can be made by incorporating a hydrophilic agent and a releasably carried adjuvant in the foam composition. Incorporation of the adjuvant in the resulting foam is achieved by the in situ reaction of a hydrophilic isocyanate-capped polyether prepolymer, a hydrophilic agent, water, adjuvant and a wetting agent.
  • the present invention provides a hydrophilic polyurethane foam composition
  • a hydrophilic polyurethane foam composition comprising the in situ reaction product of an isocyanate-capped polyether prepolymer, a hydrophilic agent capable of absorbing water, an adjuvant comprising a mono or polyhydric alcohol, a wetting agent for enhancing the wettability of the foam composition, and water.
  • the hydrophilic foam is capable of exchanging an external fluid and tightly carrying the external fluid in preference to at least a portion of the adjuvant so that upon exposure of the hydrophilic foam composition to an external fluid, such as, for example, to the exudate of a wound, the composition will absorb the external fluid and tightly carry it in preference to at least a portion of the adjuvant so that at least a portion of the adjuvant is released from the foam.
  • the present invention provides a novel wound dressing which incorporates the novel hydrophilic polyurethane foam.
  • the present invention provides a method of treating a wound which includes applying to the wound the novel hydrophilic foam composition disclosed herein or a wound dressing made therefrom.
  • composites which include the hydrophilic foam composition described herein and a method for making such composites are provided.
  • the foam composition of this invention is likewise useful in other applications where it is desired to releasably carry an adjuvant to a situs for subsequent application and to absorb an external liquid, such as water, from the situs of application.
  • Such uses include, for example, cosmetic applications.
  • a highly absorbent hydrophilic polyurethane foam composition which includes silver particles and, optionally, a releasably-carried adjuvant which is capable of being released from the composition in the presence of an external liquid.
  • the foam composition of an aspect of this invention is the in situ reaction product of a reactant composition comprising an isocyanate-capped polyether prepolymer, silver particles, a hydrophilic agent, , water and, optionally, an adjuvant and a surfactant or wetting agent.
  • the hydrophilic foam composition when applied to a moisture-laden surface will preferentially absorb moisture from that surface while releasing the adjuvant carried by the composition.
  • the hydrophilic polyurethane foam composition of the present invention is particularly useful as the absorbent pad of an occlusive or semi-occlusive wound dressing, commonly applied to injuries such as abrasions, incisions, punctures, lacerations, ulcers, sores, burns and the like to aid in bleeding cessation and in protecting the wound from contamination.
  • the foam composition of the present invention When applied to a wound, the foam composition of the present invention will absorb and retain a high volume of aqueous fluid, i.e., wound exudate, and will release any adjuvant present therein to the wound situs.
  • a wound dressing which incorporates the foam composition of the present invention may be prepared.
  • This dressing is advantageously capable of providing: enhanced hemostatic and chemical debridement characteristics; transdermal, bacteriostatic activity enhanced by, it is believed, the deposition of silver ions; as well as emollifying, demulcifying and wound cleansing characteristics.
  • the foam composition absorbs exudate moisture from the wound. In absorbing the exudate moisture, the foam swells to conform to the wound contour so as to become thermally insulative to the surface of application, while at the same time holding moisture against the surface in order to keep that surface moist.
  • the foam composition will then assist in maintaining a warm, moist and sealed wound with appropriate pH to promote epidermal resurfacing and re-epithelization.
  • a wound dressing which includes the foam composition of the present invention does not adhere to the wound and thus does not cause reinjury upon its removal from the wound. This is believed to be due to the liquid exchange and the maintenance of a moist environment about the wound.
  • the hydrophilic polyurethane foam compositions of the present invention are prepared using an isocyanate-capped polyether prepolymer.
  • these prepolymers must be safe for use in the human body, and are preferably capable of foaming in an aqueous system in the absence of a catalyst. On the other hand, such prepolymers should not dissolve in the aqueous liquid.
  • it is highly desirable that these prepolymers cure to form a porous cellular foam matrix to enable both absorption of external fluids and carriage of the chosen adjuvant in the foam composition.
  • the formation of a cellular foam matrix is preferred due to a large volume available not only for abso ⁇ tion but the containment of the chosen adjuvant. It is further desirable that the prepolymers are capable of curing in the presence of water, in the absence of catalyst, and at ambient temperature.
  • Isocyanate-capped polyether prepolymers such as those disclosed in U.S. Pat. Nos. 3,903,232 and U.S. Pat. No. 4,137,200 are suitable for use in the present invention. These prepolymers have a defined average isocyanate functionality greater than 2. These prepolymers may be capped with aromatic isocyanates, such as, for example, toluene diisocyanate or methylene diphenyl isocyanate, or with aliphatic isocyanates, such as isophorone diisocyanate. Isocyanate-capped polyether prepolymers which have been found suitable for use in the practice of the present invention include prepolymers sold under the trademark HYPOL.
  • HYPOL 2000, HYPOL 2002 and HYPOL 3000 prepolymers are derived from toluene diisocyanate.
  • FHP 2000 and FHP 2002 both have an equivalent weight (per NCO) of 625, an NCO content of 1.60 meq/g and a specific gravity of 1.19.
  • the viscosity of FHP 2000 is 18,500 cps (Brookfield LVF, #4 Spindle, 12 rpm at 25°C) and that of FHP 2002 is 20,000.
  • FHP 3000 has an equivalent weight (per NCO) of 425, an NCO content of 2.35 meq/g, a specific gravity of 1.15 and a viscosity (measured as described above) of 10,500.
  • HYPOL hydrogel is likewise derived from toluene diisocyanate. It has an NCO content of 0.5-0.9 meq/g and a viscosity of 10,000 to 12,000 cps at 25°C.
  • AQUAPOL prepolymer suitable for use in the present invention and derived from toluene diisocyanate
  • AQUAPOL prepolymers have an NCO-value of 2.5 to 3.0 and are formed from the reaction of toluene diisocyanate and an organic polyether polyol containing at least 40 percent by weight ethylene oxide adducts as described at Col. 2, lines 3-22 of U.S. Pat. No. 4,517,326.
  • a further example of an isocyanate-capped prepolymer suitable for use in the present invention and which is derived from toluene diisocyanate is sold under the trademark TREPOL, and is commercially available from Twin Rivers Engineering.
  • TREPOL prepolymers have an -NCO content of 1.4 milliequivalents per gram and a viscosity at 90°C of 4,700 cps.
  • the HYPOL FHP 4000 and HYPOL FHP 5000 prepolymers are derived from methylene diisocyanate.
  • FHP 4000 has an equivalent weight (per NCO) of 476, an NCO content of 2.10 meq/g, a Brookfield viscosity (LVF, #4 Spindle, 12 r.p.m. at 25°C) of 20,000 and specific gravity of 1.17.
  • FHP 5000 has an equivalent weight (per NCO) of 392, an NCO content of 2.55 meq/g, a Brookfield viscosity (measured as for FHP 4000) of 18,000 and a specific gravity of 1.17.
  • An example of an isocyanate-capped prepolymer suitable for use in the present invention and derived from isophorone diisocyanate is HYPOL X6100. It has an —NCO content of 1.8 meq/grams and a viscosity at 25°C of 12,000 cps.
  • the amount of prepolymer in the reactant composition used to prepare the hydrophilic foam composition is not particularly critical, but depends on a number of factors, including the proportion of other components in the reactant composition as will be described in greater detail hereinafter. However, there should be sufficient prepolymer to form a polyurethane foam, to releasably contain the adjuvant and to adequately contain the hydrophilic agent.
  • the ratio of prepolymer to hydrophilic agent should be such that the reactant composition does not degrade or break up into its separate constituents. Furthermore, while there should be sufficient prepolymer to provide integrity to the foam matrix, there should not be so much prepolymer that the resulting polyurethane composition becomes unworkable. In short, and particularly where the final composition is to be applied to the skin, the resulting foam composition is desirably relatively smooth and soft while exhibiting the desired absorbence characteristics so that it does not irritate or otherwise harm the skin. [0032] The concentration of prepolymer further depends on its isocyanate functionality and the degree of crosslinking desired in the final foam composition.
  • the reactant composition will comprise from about 20% to about 60% by weight prepolymer.
  • the reactant composition will comprise from about 45% to about 50% by weight of the prepolymer.
  • the prepolymers may be used alone or in combination.
  • the reactant composition further includes a hydrophilic agent which is inco ⁇ orated into the foam composition to absorb external liquid, such as wound exudate, and to retain such liquid in the composition.
  • a hydrophilic agent which is inco ⁇ orated into the foam composition to absorb external liquid, such as wound exudate, and to retain such liquid in the composition.
  • the hydrophilic agent When applied to a wound, the hydrophilic agent is believed to work in conjunction with the foam matrix to hold moisture at the surface of the wound. This allows healing agents exuded by the wound to be concentrated and held at the wound surface.
  • the hydrophilic agent inco ⁇ orated into the composition is believed to absorb fluid from the wound to assist thickening of the blood, i.e., it serves as a hemostat.
  • the hydrophilic agent is preferably a highly absorbent polymer, commonly known as a superabsorbent polymer.
  • a highly absorbent polymer commonly known as a superabsorbent polymer.
  • One measure of polymer absorbency is its fluid uptake capability, well known by those skilled in the art.
  • Hydrophilic agents suitable for use in the present invention include polymers that are capable of absorbing at least 50 times their weight of water, that is, such agents have a fluid uptake of at least 50 ml/g.
  • Hydrophilic agents having an even higher fluid uptake, such as of at least about 100 ml/g and even higher, that is, at least about 150 ml/g are preferred.
  • Suitable superabsorbent polymers include sodium and aluminum salts of starch grafted copolymers of acrylates and acrylamides and combinations thereof, as well as poly aery late salts.
  • other absorbent materials may be used in combination with such highly absorbent polymers, provided the fluid uptake of the overall combination used for the hydrophilic agent is greater than 50 ml/g.
  • the resulting foam composition desirably has the ability to hold at least about 3 times its weight in liquid. In the preferred embodiment, the resulting foam composition will have the ability to tightly hold at least about 3 times its weight in fluid.
  • liquid means the relative amount of liquid retained by the sample after compression, as described in detail hereinafter.
  • Hydrophilic polymers which have been found suitable for use in the foam composition of this invention are commercially available from Grain Processing Co ⁇ oration.
  • These polymers include a starch-g-poly(2-propenamide-co-2-propenoic acid, mixed sodium and aluminum salt) sold under the trademark WATER LOCK A-222; a starch-graft copolymer of polyacrylic acid and poly aery lamide having the chemical name starch-g-poly(2-propenamide-co-2-propenoic acid, sodium salt), sold under the trademark WATER LOCK A-100; a starch g-poly(2-propenamide-co-2-propenoic acid, sodium salt), sold under the trademark WATER LOCK A-200.
  • Superabsorbent polymers commercially available from Grain Processing Co ⁇ oration under the trademark WATER LOCK D-212 and WATER LOCK D-242 are likewise suitable. These polymers have the chemical name starch-g-poly(2-propenamide-co-2-propenoic acid, mixed sodium and aluminum salt).
  • the superabsorbent polymer commercially available under the trademark WATER LOCK G- 400 is also suitable for use in the making of the hydrophilic foam composition of the present invention.
  • This superabsorbent polymer may be chemically identified as a poly(2- propenamide-co-2-propenoic acid, sodium salt).
  • Other super absorbent powders suitable for use in the present invention are sold by Grain Processing Co ⁇ oration under the trademark WATER LOCK B, C, and H.
  • a suitable superabsorbent polymer is poly-2-propenoic acid, sodium salt, sold under the trademark AQUA KEEP J-500 supplied by Sanyo Co ⁇ .
  • super absorbent polymers sold by Arakawa Chemical (USA) Inc. under the trademark ARASORB are suitable.
  • the preferred hydrophilic polymers are WATER LOCK A-100, A-200, A-222 and AQUA KEEP J-500.
  • the hydrophilic polymers maybe used alone, or in combination to achieve the desired abso ⁇ tivity characteristics in the foam composition.
  • the hydrophilic agent may comprise additives in addition to the superabsorbent polymers, provided, as discussed above, the additives do not reduce the fluid uptake of the hydrophilic agent to below about 50 ml water per gram of hydrophilic agent and the fluid uptake of the final foam composition is not less than about 3 times its weight.
  • additives include methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin and combinations thereof.
  • the amount of hydrophilic agent used and the type of it, in terms of its fluid uptake, that may be satisfactorily used to make the foam composition is not critical, but is, instead, dependent on the intended application of the composition. Stated another way, the greater the quantity of external liquid to be absorbed, e.g., the greater the amount of wound exudate, the greater the amount of hydrophilic agent that should be employed. In the alternative, the greater the amount of wound exudate to be absorbed, the greater the fluid uptake of the hydrophilic agent used, should be. For example, for an ulcerated wound where there is a high volume of wound exudate, a hydrophilic agent with high uptake is desirable.
  • the amount of hydrophilic agent may need to be increased.
  • the foam may be suitable to use less hydrophilic agent or to use a hydrophilic agent with a lower fluid uptake. Determination of the type and amount of hydrophilic agent used is well within the ability of one skilled in the art in light of the disclosure herein.
  • the amount of hydrophilic agent should not be so great as to undesirably reduce the strength of the foam composition or result in a loss of polymer from the foam, although some loss of hydrophilic agent may be tolerated without adversely affecting the ability of the foam to absorb external liquid.
  • the amount of hydrophilic agent employed in the reactant composition will also depend on the absorbency of the material used. As previously indicated, it is preferable that a sufficient amount of hydrophilic agent be employed so that the resulting foam composition is capable of absorbing at least about 3 times its weight in external liquid. Typically this can be achieved by including from about 5 wt. % to about 20 wt. % hydrophilic agent in the reactant composition.
  • the foam composition of the present invention further includes silver metal.
  • the silver metal component may be in any number of forms, such as elemental silver or silver alloys, but is preferably provided as elemental silver.
  • the silver metal is also preferably provided at a high level of purity, e.g., at least about 95 percent, and preferably at least about 98 percent pure, and may include silver oxide.
  • the silver suitable for use in the present invention should be distinguished from silver salts, such as silver nitrate.
  • the silver metal in the present invention is desirably present as a particulate, in one or more forms.
  • the silver particulates may be provided as microparticles, nanoparticles, as a colloid, or in other forms.
  • the silver is desirably provided as a powder, preferably as microparticles, and more preferably as nanoparticles.
  • Providing the silver in the aforementioned powdery form is believed to provide at least the following benefits.
  • the powder may be readily added to the foam-forming composition in effective amounts without unduly affecting formation of foam having the characteristics described herein, particularly when provided as nanoparticles. In this form, undesired agglomeration of the silver particles is minimized.
  • the silver powder will not inhibit the abso ⁇ tion of wound exudate into the composition, as contrasted with a surface layer of such material which would likely inhibit such abso ⁇ tion.
  • particulate silver is not expected to disturb the release from the foam of any adjuvant that may be present therein, nor adversely affect the liquid-carrying capacity of the foam, as described more fully herein.
  • particulate silver provides an expansive surface area relative to a providing silver in the form of a layer resident on the outer surface of a dressing. This relatively expansive surface area is believed to be significant when one considers the abso ⁇ tion and release properties of the foam composition. More specifically, it is believed that the silver metal will provide antimicrobial properties upon ionization of the metal.
  • a greater concentration of ionized silver should be made available when particulate silver is used, the latter providing a relatively greater surface area per unit weight from which ions may be generated relative to a surface layer of a silver-containing compound such as silver nitrate.
  • the optional inco ⁇ oration of a releasably carried adjuvant may assist in the distribution of silver ions into the wound.
  • the adjuvant as it is released over time, may assist in delivering the silver ions to the wound surface by carrying them out of the foam composition and into the exudate layer adjacent the wound surface, facilitating the antimicrobial characteristics of the foam composition.
  • the silver particles desirably range in size up to about 15,000 nanometers, more desirably from about 1 to about 100 nm, preferably from about 5 to 40 nm, and most preferably from about 5 to about 25 nm.
  • the amount of silver inco ⁇ orated into the foam composition may also vary, but will generally range from about 0.0001 wt.% to about 5 wt.%, and desirably up to about 20 wt.%, more desirably from about 0.0001 wt.% to about 1 wt.%, or preferably up to about 0.5 wt.%, and more preferably from about 0.01 wt.% to about 3 wt.%, based on the weight of the finished foam.
  • Other antimicrobials may be included in the inventive composition. Illustrative of these are pure metals, alloys, oxides, and other compounds of gold, copper, silver and platinum, as well as halide compounds, phenol compounds and quaternary ammonium compounds.
  • the reactant composition of this invention may further include an adjuvant; preferably, a water-soluble adjuvant.
  • the adjuvant is releasably carried by the resulting foam composition for subsequent release to a chosen situs of application. Release of the adjuvant occurs in the presence of an external liquid, such as wound exudate, which is preferentially absorbed by the foam composition. Abso ⁇ tion of the external liquid causes at least a portion of the adjuvant to be released.
  • the adjuvant serves as a plasticizer for the reactant composition. It extends the curing time of the composition thereby allowing it to be more thoroughly mixed and formed. Once cured, the foam composition is softened by the adjuvant, allowing the foam to be more pliable and more easily applied to the skin surface or other surface of choice. Additionally, the adjuvant may be somewhat hygroscopic lending further to the hydrophilic nature of the foam composition.
  • Adjuvants suitable for use in the foam composition of the present invention are mono, di and polyhydric alcohols.
  • the adjuvants are water soluble so that they may be readily released from the composition upon contact of the foam composition with an external liquid.
  • the adjuvant be capable of contacting skin without adverse side effects.
  • the adjuvant comprise a chemical compound that will have the ability to open the skin pores to achieve a demulcent effect to relieve pain and/or irritation and to achieve an emollient effect to soften the skin and prevent maceration.
  • the adjuvant be compatible with therapeutic or other agents which may be carried by the adjuvant for subsequent delivery to the situs of application.
  • Suitable adjuvants include water soluble alcohols, including monols, diols and polyhydric alcohols.
  • monols include ethyl alcohol and isopropyl alcohol.
  • suitable diols are propylene glycol, polyethylene glycol and polypropylene glycol.
  • suitable polyhydric alcohols are glycerin, 1,2,4-butanetriol, trimethylolpropane, pentaerythritol and sorbitol.
  • the molecular weight of the alcohols should be less than about 1000. Mixtures of alcohols can likewise be used.
  • Glycerin is the preferred adjuvant because it has the attributes of a medicament, cosmetic or therapeutic agent.
  • the hydrophilic agent is starch- based, it is believed that glycerin coats the hydrophilic agent to form a starch glycerite.
  • fluid is absorbed by the foam, glycerin is released, thereby allowing the hydrophilic agent to swell as it absorbs fluid from the wound and causing the foam to conform to the wound contour.
  • Various additional medicaments, cosmetics and therapeutic agents may be carried with the adjuvant and released with it to the desired situs. This release thus allows the transmission of such therapeutic or other agents carried in the adjuvant to the area of application outside the foam composition, further assisting in the beneficial treatment of the wound.
  • Illustrative of therapeutic agents which may be inco ⁇ orated into the foam composition are Collasol 2400, Crotein SPA, Cromoist HYA, Crotein CAA and hydrocortisone acetate.
  • Illustrative of cosmetic agents which may be inco ⁇ orated into the foam composition are European Collagen Complex, Capture Complex Liposomes, Sardo® bath oil, a hand lotion sold under the trademark Jergens®., Noxema® skin cream, Oil of Olay® BF, Keri® lotion, Vaseline® herbal and aloe lotion, Ben Gay® ointment and Retin- A® cream.
  • the amount of adjuvant included in the reactant composition should preferably be sufficient to impart softness and pliability to the foam composition and be capable of delivering a therapeutic agent or the like, if included, to the environment of application. However, the volume of adjuvant should not be so great as to weaken or gel the composition. Generally, it has been found that the amount of adjuvant in the reactant composition should be from about 5 wt. % to about 30 wt. % of the reactant composition.
  • a wetting agent is included in the reactant composition to provide more uniform wettability of the resulting foam. The wetting agent also aids in controlling the cell size of the foam and in the reticulation of the final foam.
  • wetting agents suitable for use include non-ionic surfactants.
  • materials that may be used as the wetting agent include block copolymers of ethylene oxide and propylene oxide sold under the trademark PLURONIC by BASF Wyandotte co ⁇ oration, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, and silicone fluids.
  • PLURONIC 68 and L-62 are preferred.
  • PLURONIC F-68 aids in wound cleansing without causing tissue damage.
  • the use of PLURONIC F-68 is especially preferred because of its cleansing action, particularly because a portion of the surfactant may be released when the foam composition is exposed to the exudate of the wound.
  • the amount of wetting agent should be from about 1% to about 10% by weight of the reactant composition, preferably from about 5% to about 7% by weight.
  • the wetting agent should not react with the foam composition or any component of the foam formulation to create difficulties during foam formation or to adversely affect the desired characteristics of the foam composition in use or while being stored.
  • the source of the water required for the foaming reaction is not critical.
  • the water so required may be provided as a separate component of the reactant composition, or, for example, it may be provided by one of the other components of the reactant composition.
  • the required water may be provided with an aqueous-based cosmetic which may be inco ⁇ orated into the foam composition.
  • the type of water used is likewise not critical. However, for medical applications, purified water such as deionized or distilled water may be used. Saline solutions may also be used satisfactorily.
  • the relative proportion of prepolymer, adjuvant and hydrophilic agent included in the reactant composition can be varied over wide ranges in order to prepare a hydrophilic foam composition having the desired release and exchange characteristics previously described, while likewise providing a foam composition that is aesthetically satisfactory, insofar as its oilyness, touch, appearance and general feel.
  • the foam composition be soft and generally smooth to the touch so that it does not irritate the skin.
  • the resulting foam composition has an extended cure time with decreased ability to tightly hold external liquid and it may have an oily or spongy nonuniform surface.
  • the resulting foam composition has been found to be less uniform, has relatively poor flow and porosity characteristics, has relatively poor dimensional stability, and absorbs liquid at a slower rate.
  • the weight ratio of prepolymer to hydrophilic agent will desirably be in the range of from about 20:1 to about 20:10 and the ratio of prepolymer to adjuvant will desirably be in the range of from about 20:2 to about 20:30.
  • wetting agent employed and the amount thereof used may affect the characteristics of the resulting foam composition. It is generally desired that the wetting agent be used in an amount such that the foam is substantially uniform and readily wettable.
  • the organic phase comprises the isocyanate-capped prepolymer and optionally, but preferably, the hydrophilic agent.
  • the aqueous phase comprises the adjuvant, wetting agent, optionally the hydrophilic agent if it is not included in the organic phase, and other desired additives, such as, for example, dyes or the like to color the resulting foam. If a medicament, cosmetic or therapeutic agent is included in the reactant composition it will preferably be included in the aqueous phase.
  • a suitable substrate such as a plastic (e.g. in the form of a sheet, laminate or fibrous mat), paper, foil, or the like is provided.
  • This substrate is preferably selected so as to be air- and water-impermeable. This assists in maintaining a sterile environment adjacent the wound situs.
  • the substrate may then be coated with a medically acceptable adhesive. Such adhesives are generally well known to those skilled in the art.
  • the reactant composition as described herein is poured directly onto the adhesive where the foam is formed.
  • the foam may then be covered by a cover sheet if desired.
  • the resulting composite which comprises the substrate, adhesive, and foam may be die cut and later used itself, or it may be used as part of an occlusive or semi-occlusive wound dressing. Preferably, however, the process as set forth in U.S. Patent 5,254,301 may be utilized.
  • the resulting foam is desirably an open-celled foam, more desirably having a variety of cell sizes throughout the foam, the average cell diameter preferably ranging from about 0.005 to about 0.020 inches.
  • hydrophilic polyurethane foam composition was formulated by separately preparing an aqueous phase and an organic phase then mixing both phases at room temperature, and casting the mixture onto a film substrate.
  • the aqueous phase was prepared by dissolving the alcohol, wetting agent and colorant in distilled water using a laboratory grade magnetic stirrer. It should be noted that some surfactants (especially the paste types) required heating to 150°F before dissolution or even dispersion was possible. All other mixing was done at ambient temperature. When Pluronic F-68 was used, solution required about one hour of mixing at 1000 rpm on the stirrer to complete dissolution.
  • the organic phase was prepared by mixing the isocyanate-capped prepolymer and hydrophilic agent for about 5 to 10 seconds in a plastic vessel using an electric drill with a paint mixer blade.
  • the silver component may be added and mixed into either phase, with addition to the aqueous phase being preferred.
  • the silver is desirably pre-blended with the dry materials (e.g., hydrophilic agent), or added to one or both of the phases, prior to the mating of the two phases, as described below.
  • the silver component may be added during the mixing of the first and second phases, e.g., as the reactants are being mixed in either a batch or static mixer.
  • the methods desirably result in the silver being substantially uniformly distributed throughout the final foam material.
  • the aqueous phase was poured into the organic phase contained in a suitable mixing vessel.
  • the two phases were then mixed using a drill with the paint mixer for about 15 to about 50 seconds at about 1200 ⁇ m of the drill. Mixing time may be varied for different formulations, but generally mixing time was about 25 seconds.
  • the resulting mixture was evenly poured as a bead down a paper substrate coated with a medical grade adhesive, and covered with the silicone treated side of a 5 mil polystyrene sheet.
  • the paper substrate was about four inches wide and bordered by 0.025 inch plastic strips to contain the mixture during compression.
  • the bead was compressed and spread using a 30 pound steel cylinder.
  • the mixture was rolled at the rate of two inches per second first at 90 seconds after the two phases are combined and then after 120 seconds after combination. The foam was allowed to set for approximately seven minutes, then the cover sheet was removed.
  • the resulting foams varied in thickness from about 0.050 inch to about 0.10 inch and varied in density from about 10 to about 20 lbs/ft 3 .
  • Prepolymer A denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from toluene diisocyanate having an equivalent weight (per-NCO group) of 625, an NCO content of
  • Prepolymer B denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from toluene diisocyanate having an NCO content of 0.5-0.9 meq/g. and a viscosity at 25°C of 10,000 to 12,000 cps.
  • Prepolymer C denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from isophorone diisocyanate having an NCO content of 1.8 meq/gram and a viscosity at 25 °C of 12,000 cps. (HYPOL X6100)
  • Prepolymer D denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from toluene diisocyanate having an —NCO content of 1.4 meq/gram and a viscosity at 90°C of 4,700 cps. (TREPOL)
  • Prepolymer E denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from methylenediphenyl diisocyanate having an NCO content of 2.55 meq/g, an equivalent weight (per-NCO group) of 392 and a viscosity at 25°C of 18,000 cps. (HYPOL FHP 5000)
  • Prepolymer F denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from methylenediphenyl diisocyanate having an equivalent weight (per-NCO group) of 476, an --NCO content of 2.10 meq/g and a viscosity at 25°C of 20,000 cps. (HYPOL FHP 4000)
  • Prepolymer G denotes a diisocyanate prepolymer derived from toluene diisocyanate sold under the trademark AQUAPOL 035-0019 by Freeman Chemical Co ⁇ oration.
  • IL Hydrophilic agents [0081] A denotes a starch-g-poly(2-propenamide-co-2- propenoic acid, mixed sodium and aluminum salt) sold under the trademark WATER LOCK superabsorbent polymer A-222. [0082] B denotes a starch-g-poly(2-propenamide-co-2- propenoic acid, sodium salt) sold under the trademark WATER LOCK superabsorbent polymer A-200. [0083] C denotes a starch-g-poly(2-propenamide-co-2- propenoic acid, sodium salt) sold under the trademark WATER LOCK superabsorbent polymer A-100. [0084] D denotes a polymer consisting of 2-propenoic acid, sodium salt sold under the trademark
  • WATER LOCK superabsorbent polymer J-500 [0085] E denotes an absorbent polymer sold under the trademark ARASORB. [0086] F denotes a polyacrylic acid, sodium salt sold under the trademark AQUA KEEP J-500.
  • each of the foams of Examples 1-57 was tested to determine the release characteristics of the foam, especially the adjuvant, and to determine the ability of the foam to absorb external liquid.
  • the foams were immersed in one or more of the following: water, a normal saline solution, a 0.03% HCl solution and/or a 0.05% NaOH solution.
  • the pH of these solutions fall within the range of pH 2 to pH 12. Both the liquid held by the sample and the liquid tightly held by the sample were measured.
  • Silver may be inco ⁇ orated into one or more of these foams, in accordance with the present invention herein described, to provide illustrative embodiments of the present invention.
  • Tightly held liquid is a measure of the relative amount of liquid retained by the sample after compression. It is determined by rolling an 8 pound roller over the sample ten times, and then, using the retained liquid formula to calculate the relative proportion of liquid that was not squeezed out of the composition.
  • the % extractables is measured in deionized water, normal saline, 0.03%HC1 and/or 0.05%NaOH solutions. The percent extractable material is determined under static conditions at room temperature. In addition, the dehydrated extracted residues were visually examined for the adjuvant. In general, it was found that from about 90 to 95% of the adjuvant is released from the foam In general, when deionized water was used, the pH of the extract was 7.0.
  • the abso ⁇ tion rate was determined for the foam compositions.
  • the abso ⁇ tion rate is the time, in seconds, for 0.1 g of fluid to be absorbed by the foam composition.
  • the fluid used was either deionized water, distilled water or normal saline.
  • An abso ⁇ tion rate of less than 10 is satisfactory, and a rate of less than 5 is preferred.
  • EXAMPLES 1-8 [0095] These Examples illustrate reactant compositions used to make hydrophilic foams of the present invention. Examples 1-8 illustrate variations in the amount of water and in the wetting agent used in the reactant composition. Example 8 illustrates the wide range of the ratio of prepolymer to hydrophilic agent and prepolymer to adjuvant that can be employed in making the foam composition of this invention.
  • the reactant compositions are set forth in Table I below.
  • the retained liquid, tightly held liquid, extractable materials and abso ⁇ tion rate for the foam compositions of Examples 19 through 26 are set forth in Table VI [00103]
  • the foams of Examples 21 and 26 were acceptable as determined by all visual and measured properties. However, the foams of Examples 19 and 20 exhibit relatively poorer dimensional stability and a slower abso ⁇ tion rate.
  • the foams of Examples 22-25 were less uniform than the preferred composition of Examples 1 and 2.
  • EXAMPLES 27-32 These Examples illustrate the wide variety of hydrophilic agents that may be suitably employed in the reactant composition used to prepare the hydrophilic foam compositions of the present invention.
  • the reactant compositions are set forth in Table VII.
  • the retained liquid, tightly held liquid, extractable materials and abso ⁇ tion rate for the foam compositions of these Examples are set forth in Table VIII.
  • the foams of Examples 27-32 were all acceptable by all criteria. However, the tightly held liquid of Example 29 is somewhat low.
  • Examples 43-47 the water needed for the foaming reaction was provided by the water contained by the cosmetic.
  • the surfactant was also included in the cosmetic.
  • the retained liquid, tightly held liquid, extractable materials and abso ⁇ tion rate for the foam compositions of these Examples are set forth in Table XII.
  • the foams of Examples 41 and 47 were less hydrophilic than desired as can be seen by their high abso ⁇ tion rates. The foams of all the other Examples were satisfactory.
  • the foams of Examples 43-46 were especially soft and uniform with distinct cosmetic odor.
  • Examples 51 through 54 were more porous than desired, although the liquid retention and extractability were good.
  • the amount of extractable material for the foam of Example 49 was somewhat low.
  • EXAMPLES 58-60 Hydrophilic foams similar to Example 1 were prepared, with silver added thereto.
  • the foam of Example 58 included 5% silver by weight, based on the total weight of the finished foam product (as a powder having a particle size of from 7 to 15 micrometers.)
  • the foam of Example 59 included 0.2% silver by weight (as a powder having a particle size of from 20 to 60 nanometers).
  • the foam of Example 60 included 0.0005% silver by weight (as a colloidal silver suspension in water having an average particle size of 1.4 nanometers.)
  • the foams of Examples 58-60 were acceptable as determined by visual and measured properties.
  • the foams of Examples 58-60 were tested for antimicrobial effectiveness in vitro using the methods and organisms described below.
  • This method provides a qualitative assessment of inhibition of multiplication of microorganisms in contact with a material.
  • a broth culture of selected organisms is inoculated on the surface of an agar plate in three different directions.
  • the test sample is then centered on the agar surface. After incubation for approx. 20 hours at approx. 37°C, the agar plate is inspected for growth-free zones.
  • This method provides quantitative measurement of the kill of microbes that are on or in a material. Microorganisms of a known type are placed on the material, and allowed to remain for 1 to 24 hours at approx. 37°C . The organisms are subsequently washed from the sample. Dilution and plate counts before and after determine the reduction on number of organisms, and thus the effectiveness of the dressing.
  • Example 60 killed >99% of the organisms.
  • the material of Example 58 killed 86% of the organisms.
  • Example 59 had no growth under the sample.
  • Method 100 test with organisms P. aeruginsoa ATCC 9027, S. aureus ATCC 6538, and C. albicans ATCC 10231 for 24 hours, the material of Example 59 killed >99% of the organisms.
  • Dow Shake test with organisms P. aeruginsoa ATCC 9027, S. aureus ATCC 6538, S. aureus ATCC 33591, E. faecalis ATCC 51576, and K.

Abstract

L'invention concerne une composition de mousse hydrophile comprenant le produit réactionnel in situ d'un prépolymère de polyéther recouvert d'isocyanate, un agent hydrophile pouvant absorber de l'eau, de l'argent métallique, un agent mouillant et de l'eau.
EP03753094A 2002-05-16 2003-05-16 Compositions de mousse hydrophile presentant des proprietes antibacteriennes Withdrawn EP1516013A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38119702P 2002-05-16 2002-05-16
US381197P 2002-05-16
PCT/US2003/015694 WO2003097727A1 (fr) 2002-05-16 2003-05-16 Compositions de mousse hydrophile presentant des proprietes antibacteriennes

Publications (1)

Publication Number Publication Date
EP1516013A1 true EP1516013A1 (fr) 2005-03-23

Family

ID=29550081

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03753094A Withdrawn EP1516013A1 (fr) 2002-05-16 2003-05-16 Compositions de mousse hydrophile presentant des proprietes antibacteriennes

Country Status (4)

Country Link
EP (1) EP1516013A1 (fr)
AU (1) AU2003243262A1 (fr)
CA (1) CA2486057A1 (fr)
WO (1) WO2003097727A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820734B2 (en) 1998-10-07 2010-10-26 Tyco Healthcare Group Lp Antimicrobial lubricious coating
US7435705B2 (en) 2002-04-08 2008-10-14 Jodi Haenke Environmentally safe anti-fungal composition and methods of using same
GB2410748A (en) * 2004-02-03 2005-08-10 Johnson & Johnson Medical Ltd Medicated polyurethane foams
KR20070054642A (ko) * 2004-07-26 2007-05-29 케이씨아이 라이센싱, 아이엔씨. 지지체를 항균제로 코팅하기 위한 방법 및 이 방법에 의해형성된 제품
US20070134307A1 (en) * 2005-06-24 2007-06-14 Xiao T D Antimicrobial composite and method of manufacture and use
ES2358684T3 (es) * 2007-03-01 2011-05-12 Mölnlycke Health Care Ab Estructura de espuma que contiene plata.
EP2143744A1 (fr) 2008-07-09 2010-01-13 Bayer MaterialScience AG Mousses de polyuréthane hydrophile et aliphatique
EP2289959A1 (fr) 2009-08-29 2011-03-02 Bayer Material Science AG Mousse de polyuréthane hydrophile et aliphatique
EP2336211A1 (fr) 2009-12-12 2011-06-22 Bayer MaterialScience AG Mousse de polyuréthane hydrophile et aliphatique
WO2011083144A1 (fr) 2010-01-11 2011-07-14 Bayer Materialscience Ag Mousses de polyuréthane aliphatique hydrophile
WO2012055834A1 (fr) 2010-10-27 2012-05-03 Bayer Materialscience Ag Mousses polyuréthanne aliphatiques hydrophiles
US8901188B2 (en) 2011-06-16 2014-12-02 Kimberly-Clark Worldwide, Inc. Antimicrobial polyurethane foam and process to make the same
WO2017019868A1 (fr) * 2015-07-28 2017-02-02 Curaline Inc. Systèmes et procédés de production de mousses hydrophiles
GB201711179D0 (en) * 2017-07-12 2017-08-23 Smith & Nephew Wound care materials, devices and uses
GB201711181D0 (en) * 2017-07-12 2017-08-23 Smith & Nephew Polymer foam material, device and use
GB201711183D0 (en) 2017-07-12 2017-08-23 Smith & Nephew Antimicrobial or wound care materials, devices and uses
EP3850029A1 (fr) 2019-08-09 2021-07-21 Safas Saf Plastik Sanayi Ve Ticaret Anonim Sirketi Mousse de polyuréthane souple modifiée au bore pour l'hygiène et son procédé de production
EP4041326A4 (fr) * 2019-10-10 2023-11-01 Keneric Healthcare, LLC Agent tensioactif à base de mousse
CN114306709A (zh) * 2021-12-31 2022-04-12 泰州市榕兴医疗用品股份有限公司 一种抗菌聚氨酯海绵及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123707D0 (en) * 1991-11-07 1992-01-02 Johnson & Johnson Medical Ltd Polyurethane foam
US6326410B1 (en) * 1992-11-04 2001-12-04 Johnson & Johnson Medical, Inc. Wound dressing comprising polyurethane foam

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03097727A1 *

Also Published As

Publication number Publication date
WO2003097727A1 (fr) 2003-11-27
AU2003243262A1 (en) 2003-12-02
CA2486057A1 (fr) 2003-11-27

Similar Documents

Publication Publication Date Title
US5064653A (en) Hydrophilic foam compositions
US5065752A (en) Hydrophilic foam compositions
WO2003097727A1 (fr) Compositions de mousse hydrophile presentant des proprietes antibacteriennes
JP3345059B2 (ja) ポリウレタンフォームの製法
US20220331478A1 (en) Systems and Methods for Making Hydrophilic Foams
US5254301A (en) Process for preparing a sheet of polymer-based foam
AU2003208303B2 (en) A wound care device
EP1159972B1 (fr) Pansements microbicides contenant des composés métalliques
US8821916B2 (en) Medical dressing comprising an antimicrobial silver compound
CA2678034C (fr) Structure en mousse contenant de l'argent
CA2082365C (fr) Pansement contenant de la mousse de polyurethanne
EP1603600B1 (fr) Compositions polymeres contenant des composes bioactifs d'argent, de cuivre ou de zinc, articles medicaux et procedes associes
GB2399289A (en) Hydrogel wound dressing
JP2002511314A (ja) 傷包帯材において使用するためのポリウレタン発泡体
WO2004080500A1 (fr) Materiaux hydrocolloides destines a etre utilises dans la cicatrisation des blessures
CN112250901B (zh) 一种多功能互穿网络聚合物乳液在聚氨酯软泡塑料改性中的应用
AU624808B2 (en) Hydrophilic foam compositions
EP4338762A1 (fr) Procédé de production d'une composition d'hydrogel hautement absorbante à des fins médicales, en particulier pour le traitement de plaies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080603